Abstract
Purpose: Deep vein thrombosis (DVT) is increasingly recognized as a major complication of thalidomide (T; Thal) and lenalidomide (R; Rev) based therapy for multiple myeloma. Estimated incidence varies widely in the literature. There is no consensus on specific risk factors, indications for thromboprophylaxis or the agent of choice for DVT prophylaxis. The purpose of this study was to develop a consensus among members of the IMWG.
Patients and Methods: A survey was electronically mailed to 67 IMWG members on July 21, 2006 and consisted of 24 multiple-choice questions.
Results: Twenty-three IMWG members (34%) sent in their responses by the cut-off date. All (100%) felt that DVT was an important question, but most (95%) did not avoid Thal/Rev based therapy because of the DVT risk. Overall results are summarized in the Table below. A majority of physicians felt that concomitant therapy with high dose dexamethasone (90% of physicians), alkylators (55%), doxorubicin/liposomal doxorubicin (90%), and erythropoietin (75%) increase the risk of DVT associated with Thal or Rev based therapy. Aspirin (81 mg or 325 mg per day) was the preferred choice of prophylaxis when necessary. However, 65% of respondents preferred warfarin to a therapeutic INR or LMW heparin if either doxorubicin or liposomal doxorubicin was added to the regimens. Most (95–100%) felt that DVT prophylaxis was not indicated for: VAD, MP, bortezomib +/− dexamethasone regimens. Seventy-five percent felt it to be safe to resume therapy with Thal/Rev after therapeutic anticoagulation. Most (95%) believed randomized trials were needed.
Conclusion: DVT is recognized as a major clinical problem associated with Thal/Rev containing regimens. Most respondents felt that the DVT risk did not warrant any prophylaxis when either Thal or Rev were used as single agents. Aspirin was the preferred form of DVT prophylaxis for most Thal/Rev containing regimens, except when doxorubicin/liposomal doxorubicin or melphalan were added. Additional responses will be analyzed both electronically and by conference call prior to the meeting.
| Therapy . | Estimated incidence of DVT (% respondents) . | Choice of thromboprophylaxis (% respondents) . |
|---|---|---|
| Single agent thal | <5% (61%) | None (65%) |
| Single agent Rev | <5% (80%) | None (65%) |
| Thal-Dex | 10–20% (52%) | Aspirin (60%) |
| Rev-Dex | 10–20% (48%) | Aspirin (60%) |
| MPT | 10–20% (65%) | Aspirin (40%) |
| R-MP | 5–10% (57%) | Aspirin (70%) |
| Therapy . | Estimated incidence of DVT (% respondents) . | Choice of thromboprophylaxis (% respondents) . |
|---|---|---|
| Single agent thal | <5% (61%) | None (65%) |
| Single agent Rev | <5% (80%) | None (65%) |
| Thal-Dex | 10–20% (52%) | Aspirin (60%) |
| Rev-Dex | 10–20% (48%) | Aspirin (60%) |
| MPT | 10–20% (65%) | Aspirin (40%) |
| R-MP | 5–10% (57%) | Aspirin (70%) |
Disclosure: No relevant conflicts of interest to declare.
Author notes
Corresponding author
